{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Pre-Conditioning", "query": { "intervention": "Tetanus Pre-Conditioning" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Pre-Conditioning&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T15:54:07.087Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03688178", "title": "DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Varlilumab", "type": "BIOLOGICAL" }, { "name": "Td", "type": "BIOLOGICAL" }, { "name": "Unpulsed DCs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Annick Desjardins, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2020-08-26", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03688178" }, { "nct_id": "NCT02366728", "title": "DC Migration Study for Newly-Diagnosed GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Astrocytoma, Grade IV", "Giant Cell Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Unpulsed DCs", "type": "BIOLOGICAL" }, { "name": "Td", "type": "BIOLOGICAL" }, { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs", "type": "BIOLOGICAL" }, { "name": "111In-labeled DCs", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 64, "start_date": "2015-10-12", "completion_date": "2020-10-31", "has_results": true, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02366728" }, { "nct_id": "NCT03299309", "title": "PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Medulloblastoma", "Recurrent Brain Tumor, Childhood", "Malignant Glioma" ], "interventions": [ { "name": "PEP-CMV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Landi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "3 Years to 35 Years" }, "enrollment_count": 30, "start_date": "2018-06-29", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03299309" }, { "nct_id": "NCT05609994", "title": "ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Low Grade Glioma of Brain" ], "interventions": [ { "name": "PEPIDH1M vaccine + vorasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Katy Peters, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2025-07-15", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05609994" }, { "nct_id": "NCT05096481", "title": "PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma" ], "interventions": [ { "name": "PEP-CMV", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Tetanus Diphtheria Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 120, "start_date": "2024-07-18", "completion_date": "2030-06-15", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 13, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096481" }, { "nct_id": "NCT03927222", "title": "Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Tetanus-Diphtheria Toxoid (Td)", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "111-Indium-labeling of Cells for in vivo Trafficking Studies", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-09-30", "completion_date": "2023-02-10", "has_results": true, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03927222" }, { "nct_id": "NCT03396575", "title": "Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma (DIPG)", "Brain Stem Glioma" ], "interventions": [ { "name": "TTRNA-DC vaccines with GM-CSF", "type": "BIOLOGICAL" }, { "name": "TTRNA-xALT", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide + Fludarabine Lymphodepletive Conditioning", "type": "DRUG" }, { "name": "Dose-Intensified TMZ", "type": "DRUG" }, { "name": "Td vaccine", "type": "DRUG" }, { "name": "Autologous Hematopoietic Stem Cells (HSC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "3 Years to 30 Years" }, "enrollment_count": 11, "start_date": "2018-07-17", "completion_date": "2025-03-20", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03396575" }, { "nct_id": "NCT06639607", "title": "PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Midline Glioma", "Diffuse Midline High-grade Glioma", "Medulloblastoma", "Ependymoma" ], "interventions": [ { "name": "PEP-CMV vaccine", "type": "BIOLOGICAL" }, { "name": "Tetanus booster", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "4 Years to 25 Years" }, "enrollment_count": 68, "start_date": "2026-08-31", "completion_date": "2051-06-30", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 3, "location_summary": "St Louis, Missouri • Durham, North Carolina • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06639607" }, { "nct_id": "NCT02193347", "title": "IDH1 Peptide Vaccine for Recurrent Grade II Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Cancer", "Brain Neoplasm, Primary", "Brain Neoplasms, Recurrent", "Brain Tumor", "Cancer of the Brain" ], "interventions": [ { "name": "PEPIDH1M vaccine", "type": "BIOLOGICAL" }, { "name": "Tetanus-Diphtheria Toxoid (Td)", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Katy Peters, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-01-28", "completion_date": "2020-02-03", "has_results": true, "last_update_posted_date": "2023-12-01", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02193347" }, { "nct_id": "NCT02261961", "title": "Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sarcopenia", "Aging", "Immune Function" ], "interventions": [ { "name": "TDAP", "type": "BIOLOGICAL" }, { "name": "Acute Resistance Exercise", "type": "OTHER" }, { "name": "Resistance Exercise Training", "type": "OTHER" }, { "name": "Post-training Follow-up", "type": "OTHER" }, { "name": "Nutritional Supplement (Muscle Armor)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo (Kool-Aid)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "60 Years to 80 Years" }, "enrollment_count": 59, "start_date": "2014-07-23", "completion_date": "2019-09-30", "has_results": true, "last_update_posted_date": "2021-09-28", "last_synced_at": "2026-09-02T15:54:07.087Z", "location_count": 1, "location_summary": "North Little Rock, Arkansas", "locations": [ { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02261961" } ] }